US$ 25.27
maximum weight loss tirzepatide surmount trials For the first time, and semaglutide were put in the same trial. SURMOUNT-5. Phase 3b RCT. 751 adults with obesity, no diabetes. 72 weeks. Both drugs at tolerated dose. The Tirzepatide once weekly for the
Description
& Hamersky, C

Great product and instructions

doi: 10.4088/PCC.25cr03931

Many patients begin with the injection form due to superior bioavailability and dose flexibility, then reassess after 8-12 weeks using waist circumference and how clothes fit as practical measures of visceral fat loss

Up to 19.6 cm reduction in waist circumference , the placebo group reduced only 2.6 cm
Tirzepatide appears to work by influencing brain reward systems while simultaneously affecting metabolic complications common in alcohol disorders
